logo
Plus   Neg
Share
Email

CenturyLink Posts Q4 Loss

CenturyLink Inc. (CTL) Wednesday reported a loss for the fourth quarter. Adjusted earnings trumped Wall Street estimates, while revenues were in line. However, shares of the company slipped over 8% in the extended trading session.

Monroe, Louisiana-based CenturyLink's fourth-quarter loss was $2.41 billion or $2.26 per share, compared to profit of $1.12 billion or $1.26 in the same period last year.

Excluding items, CenturyLink' adjusted earnings were $394 million or $0.37 per share for the period. On average, 13 analysts polled by Thomson Reuters expected earnings of $0.32 per share for the quarter.

Revenues for the quarter dropped to $5.78 billion from $6.01 billion in the same period last year. Analysts had a consensus revenue estimate of $5.78 billion.

CEO Jeff Storey said, "In 2019, we are shifting our focus from integration to transformation. We are focused on profitable revenue growth in our business markets and believe the scope and scale of our global assets, along with our innovative product portfolio, position us to succeed."

CTL closed Wednesday's trading at $14.70, up $0.15 or 1.03% on the NYSE. The stock, however, slipped $1.30 or 8.84% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT